Sign in
Taking peoplePhase 4

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

Key facts

Who runs it
Northern Jiangsu People's Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
336 people, planned
Started
2 Mar 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hydrocortisone plus Fludrocortisone
  • Standard care
Record updated
4 March 2026

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • (1)18≤Age≤90; (2)Diagnosis of septic shock within 12 h

Who cannot take part

  • Systemic corticosteroid therapy within the last 3 months before septic shock
  • High-dose steroid therapy
  • Patients meeting any of the following conditions will be excluded:
  • Known allergy to hydrocortisone or fludrocortisone
  • Presence of gastrointestinal bleeding, perforation, or other conditions requiring fasting
  • Anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician)
  • Immunosuppression
  • Pregnant
  • Refusal of the attending staff or patient family
  • Current participation in another clinical trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.

The 2 groups in the trial

  • Hydrocortisone plus FludrocortisoneTreatment being tested

    Hydrocortisone: 200 mg per day administered by continuous intravenous infusion for up to 7 days or until ICU discharge, whichever occurs first. Fludrocortisone: 50 μg administered orally or via nasogastric tube once daily for up to 7 days or until ICU discharge, whichever occurs first.

  • Standard careExisting treatment, for comparison

    Patients will receive standard care for septic shock according to current international guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures, including the use of hydrocortisone at the discretion of the treating physician, but without fludrocortisone.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Initiation of Hydrocortisone and Fludrocortisone in Adult Patients With Septic Shock:A Prospective Randomized Controlled Clinical Trial
Criteria questions
Built from NCT07383103, who can take part
Record updated
4 March 2026